CYTOKINETICS (CYTK) CEO Robert Blum Exercises Options, Sells Shares

What Happened Robert I. Blum, President & CEO and a director of Cytokinetics (CYTK), exercised options to acquire 7,500 shares at $10.60 per share (total exercise cost $79,500) on 2026-09-28. Those 7,500 shares were sold the same day in an open-market transaction at $65.46 per share, generating proceeds of $490,950. The Form 4 also reports a derivative disposition of 7,500 shares at $0, which reflects the conversion/cancellation of the derivative instrument tied to the exercise.

Key Details

• Transaction date: 2026-09-28
• Option exercise: 7,500 shares at $10.60 — $79,500 paid (code M)
• Open-market sale: 7,500 shares at $65.46 — $490,950 proceeds (code S)
• Derivative disposition: 7,500 shares at $0 reported (code M) — reflects conversion of the derivative on exercise
• Shares owned after transaction: not specified in the provided Form 4 excerpt
• Footnotes: F1 and F2 note shares held by The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust; Mr. Blum is a co-trustee and disclaims beneficial ownership of those trust shares
• Filing timeliness: Form filed on 2026-09-28 for transactions on 2026-09-28; no indication in the excerpt that the filing was late

Context This was a common cashless-style sequence: exercise of options followed by immediate sale of the acquired shares. Purchases are generally more informative as bullish signals; here the immediate sale converted option value to cash and is a routine insider liquidity event rather than a clear buy signal.